#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors byKathleen Lau January 21, 2022 0
#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma byKathleen Lau December 31, 2021 0
#VisualAbstract Cutaneous reactions alone following administration of messenger RNA COVID-19 vaccines are not a contraindication to revaccination byKathleen Lau July 2, 2021 0
#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy byKathleen Lau June 10, 2021 0
